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Abstract
Background: The purpose of this study was to characterize total homocysteine (tHcy) levels at
birth in preterm and term infants and identify associations with intraventricular hemorrhage (IVH)
and other neonatal outcomes such as mortality, sepsis, necrotizing enterocolitis,
bronchopulmonary dysplasia, and thrombocytopenia.
Methods: 123 infants < 32 weeks gestation admitted to our Level III nursery were enrolled. A
group of 25 term infants were enrolled for comparison. Two blood spots collected on filter paper
with admission blood drawing were analyzed by a high performance liquid chromatography (HPLC)
method. Statistical analysis included ANOVA, Spearman's Rank Order Correlation and Mann-
Whitney U test.
Results: The median tHcy was 2.75 µmol/L with an interquartile range of 1.34 – 4.96 µmol/L.
There was no difference between preterm and term tHcy (median 2.76, IQR 1.25 – 4.8 µmol/L vs
median 2.54, IQR 1.55 – 7.85 µmol/L, p = 0.07). There was no statistically significant difference in
tHcy in 31 preterm infants with IVH compared to infants without IVH (median 1.96, IQR 1.09 –
4.35 µmol/L vs median 2.96, IQR 1.51 – 4.84 µmol/L, p = 0.43). There was also no statistically
significant difference in tHcy in 7 infants with periventricular leukomalacia (PVL) compared to
infants without PVL (median 1.55, IQR 0.25 – 3.45 µmol/L vs median 2.85, IQR 1.34 – 4.82 µmol/
L, p = 0.07). Male infants had lower tHcy compared to female; prenatal steroids were associated
with a higher tHcy.
Conclusion: In our population of preterm infants, there is no association between IVH and tHcy.
Male gender, prenatal steroids and preeclampsia were associated with differences in tHcy levels.
Background
Intraventricular hemorrhage (IVH) and periventricular
leukomalacia (PVL) are significant causes of morbidity
and mortality in the preterm infant population, yet
aspects of the multifactorial pathophysiology leading to
these CNS insults remain unclear. Petaja et al has sug-
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gested that thrombophilia may play a role in the etiology
of IVH in preterm infants [1]. They identified 32% of
infants with IVH as having abnormal prothrombotic fac-
tors [1]. Others have implicated activated coagulation fac-
tors in cerebral white matter damage; these activated
factors are thought to cause injury by exacerbating inflam-
mation rather than by occlusion of cerebral vessels [2].
Additionally, association has been found between hyper-
homocysteinemia in term newborns and the risk of
ischemic or hemorrhagic stroke [3]. The neonatal out-
comes associated with abnormal coagulation factors and
thrombophilia in preterm infants are not well under-
stood. Homocysteine (Hcy), an important amino acid
studied in adult thrombophilia, has not been extensively
investigated as a possible contributor to preterm neonatal
CNS pathologies [4].
Hyperhomocysteinemia in adults is well known to be
associated with a hypercoagulable state and cardiovascu-
lar disease [4-6]. Hcy also plays an important role in preg-
nancy [7]. Elevated maternal total homocysteine (tHcy)
levels are known to be associated with preeclampsia, pre-
maturity, and low-birth weight [7-9]. Furthermore, mater-
nal hyperhomocysteinemia has also been reported to be
associated with placental abruption, early recurrent fetal
loss, and growth retardation, as well as neural tube defects
[7,10-12]. Interestingly, the tHcy level measured in preg-
nancy is lower than in the nonpregnant state [13,14], and
maternal tHcy correlates directly with neonatal levels
[15,16]. It has been suggested that tHcy levels in infants
are dependent on gestational age at birth, postnatal age
and neonatal diet [17-20]. Hongsprabhas characterized
tHcy levels in 9 preterm versus 4 term infants and demon-
strated lower levels in the preterm group [17]. Despite
these documented effects of Hcy on a pregnancy and the
fetus, very little is known of the role of Hcy in infants.
We theorized that an elevation of tHcy may promote
thrombosis in the germinal matrix venules resulting in a
post-infarction hemorrhage. We hypothesized that ele-
vated levels of tHcy in preterm infants are associated with
vascular complications, specifically IVH. The purposes of
this investigation were to 1) characterize tHcy levels at
birth in a preterm and term population and 2) determine
if tHcy levels at birth are associated with IVH and other
neonatal morbidities. This is an important investigation
to undertake given that if an association exists between
the neonatal tHcy levels and IVH or other neonatal mor-
bidities, potentially modifying Hcy in pregnant mothers
may affect neonatal outcome.
Methods
This was a prospective cohort study in which infants < 32
weeks gestation who were admitted to the level III Special
Care Nursery at Christiana Care Hospital from February
2002 to November 2002 were eligible. Patients were eligi-
ble regardless of family history of hematologic disorders
or past pregnancy outcomes. Two blood spots were col-
lected on filter paper specimens simultaneously with
admission blood drawing. Samples were also collected for
comparison on a convenience sample of term infants (≥
37 weeks gestation) who were admitted to the Special
Care Nursery during the same time period. Blood from
both groups was drawn by either heel-stick procedure or
arterial puncture if blood was being obtained for other
purposes and was collected at < 24 hours of postnatal age.
Written informed consent was obtained. The Institutional
Review Board at Christiana Care Hospital approved this
study.
Filter paper specimens were batched and refrigerated until
transport to the Baylor Institute of Metabolic Disease
where they were analyzed for tHcy by a method utilizing
high performance liquid chromatography (HPLC) cou-
pled to electrochemical (Coulometric) detection. This
method of homocysteine analysis from newborn screen-
ing cards has been previously used and validated by others
and ourselves [21,22].
Clinical data, including all recorded diagnoses and plate-
let counts, were collected from the patient's chart. In addi-
tion to IVH, other common neonatal morbidities, such as
cystic PVL and necrotizing enterocolitis, which are
thought to involve inflammation or vascular compromise
were chosen as measured secondary outcomes. Clinical
chorioamnionitis was a clinical diagnosis made by the
obstetrician using maternal symptoms of fever, uterine
tenderness, or foul-smelling amniotic fluid. Neonatal sep-
sis was defined as culture positive; necrotizing enterocoli-
tis was defined using Bell's staging criteria, stage II or
greater [23]. Admission illness severity was documented
using SNAP (Score for Neonatal Acute Physiology) [24].
Bronchopulmonary dysplasia was defined as oxygen
dependency at 36 weeks corrected gestational age. Throm-
bocytopenia was defined as a platelet count of less than
150,000. Infants were followed for all primary and sec-
ondary outcomes during their initial hospitalization until
time of discharge.
All cranial ultrasounds were interpreted by a pediatric
radiologist who was blinded to the infant's tHcy result.
Cranial ultrasounds were obtained through the anterior
fontanel using a 7.5 MHz transducer. The highest grade
IVH as defined using Papile's classification was recorded
[25]. Severe IVH was considered grade III and IV. Cystic
PVL was defined as echolucent cysts in the periventricular
white matter. Screening head ultrasounds (HUS) in our
institution are typically performed in infants < 32 weeks
gestation on the fourth postnatal day and at one month ofBMC Pediatrics 2007, 7:38 http://www.biomedcentral.com/1471-2431/7/38
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age with additional ultrasounds done at the discretion of
the neonatology team.
A sample size calculation determined 125 total preterm
infants were necessary to enroll to show a 33% difference
in tHcy in infants with IVH with a β of 0.8 and α of 0.05.
We used the previously reported mean tHcy level of 3.8 ±
2.4 µmol/L reported by Hongsprabhas et al in preterm
infants for calculations [17]. The historical incidence of
IVH in preterm very low birth weight infants at our insti-
tution is approximately 25%. We enrolled 125 preterm
infants but excluded two based on errors with the tHcy
assay. Mann-Whitney U test and Spearman Rank Order
Correlation were used to analyze data that was not nor-
mally distributed. ANOVA was utilized for normally dis-
tributed data. Levine's test for homogeneity was used to
differentiate normally from non-normally distributed
data. A p  value of < 0.05 was considered significant.
Results are reported as median and interquartile range.
Results
Patient demographics are represented in Table 1. The
median tHcy was 2.75 µmol/L with an interquartile range
of 1.34 – 4.96 µmol/L. 123 preterm infants were com-
pared to a sample of 25 term infants. There was no differ-
ence between preterm and term tHcy (median 2.76, IQR
1.25 – 4.8 µmol/L vs median 2.54, IQR 1.55 – 7.85 µmol/
L, p = 0.07). In the preterm infants, there was no associa-
tion between tHcy and gestational age (r = 0.15, p = 0.1)
or birth weight (r = 0.14, p = 0.2) using Spearman's Rank
Order Correlation.
There was no statistically significant difference in tHcy in
31 preterm infants with IVH compared to those infants
without IVH (median 1.96, IQR 1.09 – 4.35 µmol/L vs
median 2.96, IQR 1.51 – 4.84 µmol/L, p = 0.43). Addi-
tionally, there was no significant difference in tHcy in the
16 infants with severe IVH compared to those infants
without severe IVH (median 1.49, IQR 1.11 – 3.98 µmol/
L vs median 2.83, IQR 1.42 – 4.8 µmol/L, p = 0.26). Cystic
PVL was diagnosed in 7 patients and tHcy levels were not
statistically significantly different in this group compared
to infants without cystic PVL (median 1.55, IQR 0.25 –
3.45 µmol/L vs median 2.85, IQR 1.34 – 4.82 µmol/L, p =
0.07).
Male infants had lower tHcy compared to female (median
1.83, IQR 1.08 – 4.16 µmol/L vs median 3.26, IQR 1.95 –
5.54 µmol/L, p = 0.01). Prenatal steroids were associated
with a higher tHcy (median 3.15, IQR 1.51 – 5.23 µmol/
L vs median 1.82, IQR 1.14 – 3.29 µmol/L, p = 0.03) com-
pared to infants born to mothers who did not receive ster-
oids. Maternal preeclampsia also was associated with
higher neonatal tHcy levels (median 4.32, IQR 2.31 –
6.28 µmol/L vs median 2.16, IQR 1.14 – 3.76 µmol/L, p =
0.01) compared to infants without maternal preeclamp-
sia.
When tHcy was examined for association with other
major morbidities of prematurity, there were no differ-
ences found in Hcy levels and mortality, sepsis, necrotiz-
ing enterocolitis, or bronchopulmonary dysplasia (data
represented in Table 2). Table 2 also describes the tHcy
levels in infants with thrombocytopenia during the first 3
days of life compared to infants without thrombocytope-
nia. There was no association with thrombocytopenia and
tHcy level. There was also no correlation with platelet
count at birth or during the 1st 3 days of life with tHcy
(data not shown).
Discussion
In our population of preterm infants, there was no associ-
ation between tHcy measured at birth and IVH. We can-
not exclude an association between tHcy level beyond
birth and brain injury given that we measured values
within the first 24 hours of life. Although an increased risk
of other prothrombotic factors such as Factor V and pro-
thrombin gene mutations in preterm infants with IVH was
reported previously [1], IVH does not appear to be associ-
ated with an elevated tHcy in our study population as we
had hypothesized.
We were able to successfully measure tHcy levels in 148
mostly preterm infants from filter paper specimens and
describe the normal distribution of tHcy in our study pop-
ulation. The tHcy level in our infants is similar to the
mean of 3.8 µmol/L described by Hongsprabhas et al in 9
Canadian preterm infants [17]. Comparable values were
also reported in a US study which described a mean tHcy
level of 3.49 µmol/L from term umbilical arterial samples
[26]. Others have documented varying tHcy levels at birth
from 3.8 to 7.9 µmol/L [13,16,27,28]; some have sug-
gested that these differences may be due to cultural varia-
tions or differences in fortification of foods [29]. Higher
tHcy values have been described in the umbilical vein as
compared to umbilical artery and this may account for
some of the variation as well [26].
Table 1: Patient demographics for all infants
Term
n = 25
Preterm
n = 123
Gestational age (weeks) 37.9 ± 1.8 28.4 ± 2.4
Birth weight (g) 3343 ± 800 1188 ± 358
Male gender 20 (80%) 65 (57%)
Preeclampsia 1 (4%) 33 (27%)
Chorioamnionitis 3 (12%) 7 (6%)
Prenatal steroids 2 (8%) 74 (60%)BMC Pediatrics 2007, 7:38 http://www.biomedcentral.com/1471-2431/7/38
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Previous authors have suggested differences in Hcy based
on gestational age with tHcy levels increasing with GA
[17]. We did not identify any correlation of tHcy with ges-
tational age in our population of infants. There also were
no differences between preterm and term tHcy level. Our
findings of increased tHcy in infants exposed to maternal
steroids and preeclampsia may have elevated the tHcy in
the preterm population contributing to our lack of differ-
ence between term and preterm tHcy. To our knowledge,
our investigation examined the widest variation in GA
(22–36 weeks) and the lowest mean gestation (29 ± 4
weeks) in relation to tHcy. Our data are consistent with
Minet who found no correlation between tHcy and gesta-
tional age [19]. It has been previously described that ele-
vated tHcy levels are associated with increased rates of
prematurity while the natural history of maternal tHcy is
to lower with pregnancy [7,14]. In 434 Chinese women,
the risk of preterm birth was nearly 4-fold higher among
women with preconception tHcy concentrations ≥ 12.4
µmol/L compared with women who had lower concentra-
tions [9]. These opposing factors may also explain our
lack of clear relationship between tHcy and GA.
We evaluated tHcy within the first day of life to negate any
effects the neonatal diet may have. Based on our data we
cannot comment on any association between tHcy levels
in infants beyond the immediate postnatal period and
IVH. The neonatal diet has been shown to clearly affect
Hcy possibly through differences in intake of the essential
vitamins necessary for folate metabolism [13,18,19]. Dif-
ferences in maternal and neonatal Vitamin B12 levels
account for much of the variation in tHcy. Preterm infants
should not have received enteral nutrition or parenteral
nutrient intake with folate or Vitamin B12 at the time of
the blood draw. Therefore, the initial parenteral fluid
should not have affected the tHcy value. Neonatal levels
measured on the first day of life should predominantly be
reflective of maternal levels and not influenced by diet or
postnatal age changes.
We found lower tHcy in males as compared to females in
our study sample. This has been described previously in
newborn children by Refsum et al [30]. The opposite has
been reported in adult males with some finding slightly
higher tHcy values [4]. This finding in adults may be
related to gender related differences in diet or hormonal
influences which would be different in the postpubertal
population compared to neonates. However, others have
also reported no differences in tHcy related to gender;
Minet found no difference in 123 term healthy infants as
did Monsen et al in infants up to one year of age [19,20].
Additionally, prenatal steroids were associated with
higher tHcy values in our neonatal population. This is the
first study to describe this effect. Analogous results of ele-
vated tHcy levels have been documented in body builders
using anabolic steroids [31]. In our neonatal population,
this difference in tHcy associated with prenatal steroids
did not appear to be related to differences in neonatal
morbidities and therefore may not be clinically important
in at least the short term management of infants.
There were several limitations to our study. We only meas-
ured tHcy within 24 hours after birth. Future investiga-
tions to exclude an association between tHcy and IVH or
cystic PVL might characterize tHcy beyond 24 hours but
during the first several days of life, which is the highest
risk period for IVH. The majority of IVH in preterm infants
is known to occur in the first three days of life. Due to the
small number of cases of cystic PVL in our study popula-
tion, our population may have been under powered to
show small differences in tHcy with cystic PVL. We also
did not measure other likely important variables such as
folate, vitamin B12, or maternal tHcy. However, given our
limitations, our findings are similar to those recently pre-
sented by Kenet et al [32]. Their group demonstrated no
association in 166 preterm infants evaluated for multiple
prothrombotic factors with neonatal complications.
Importantly, most tHcy samples in their study group were
measured in the first one to four weeks of life, but still
demonstrated no association with IVH or PVL. Our cur-
rent study differs largely in the timing of the measured
tHcy; we obtained all tHcy samples within 24 hours,
before the majority of IVH or cystic PVL occurs.
Table 2: Neonatal outcomes in 123 preterm infants versus tHcy
Neonatal outcome Number of events tHcy (µmol/L) median, (IQR) tHcy (µmol/L) median, (IQR) p
yes no
Mortality 13 3.08 (1.83 – 4.98) 2.75 (1.25 – 4.77) 0.6
Sepsis 36 2.52 (1.09 – 3.40) 2.76 (1.42 – 4.85) 0.11
Necrotizing enterocolitis 8 2.20 (0.88 – 3.25) 2.83 (1.34 – 4.85) 0.25
Bronchopulmonary dysplasia 22 2.92 (1.14 – 5.23) 2.75 (1.42 – 4.8) 0.81
Thrombocytopenia, day of life 1 24 2.47 (1.38 – 4.37) 2.85 (1.34 – 4.85) 0.72
Thrombocytopenia, day of life 1–3 35 2.42 (1.12 – 4.29) 2.75 (1.17 – 5.19) 0.64BMC Pediatrics 2007, 7:38 http://www.biomedcentral.com/1471-2431/7/38
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Conclusion
Homocysteine, while an important thrombophilic factor
in certain maternal and fetal morbidities, is not clearly
associated with common neonatal morbidities, specifi-
cally IVH in our population of premature infants. It
remains unclear if tHcy contributes to vascular compro-
mise that may be important in other neonatal patholo-
gies. Further investigations are essential to fully
understand the role of tHcy in neonatal coagulation and
its clinical consequences.
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